This article is more than 5 years old. Information may no longer be current.
VIDEO: Fleischmann discusses methotrexate, glucocorticoid discontinuation in patients treated with tofacitinib
WASHINGTON — At the American College of Rheumatology Annual Meeting, Roy M. Fleischmann, MD, clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center and in private practice at Rheumatology Associates in Dallas, Texas, spoke about the effect of discontinuation of methotrexate or glucocorticoids on the maintenance of clinical efficacy for tofacitinib in patients with rheumatoid arthritis.
In the study, the data from two open-label, long-term extension studies were analyzed. Researchers found patients with rheumatoid arthritis who achieve a high-level response with tofacitinib may be able to discontinue methotrexate or glucocorticoids and maintain response.